SCHEMBL1019005

SCHEMBL1019005

CC(C)(C)OC(=O)N1CCN(c2ccc(CN)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.62
LMNA P02545 3/20 0.62
ALDH1A1 P00352 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
CYP2C19 P33261 1/20 0.61
HTT P42858 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
DDB1 Q16531 1/20 0.55
CRBN Q96SW2 1/20 0.55
GPR119 Q8TDV5 9/20 0.55
NAMPT P43490 1/20 0.54
TSHR P16473 1/20 0.51
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
ESRRB O95718 1/20 0.48
ESR1 P03372 1/20 0.48
ESRRA P11474 1/20 0.48
ESRRG P62508 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19212323 0.89 MAPT (0.60) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL5573222 0.88 MAPT (0.76) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL3807661 0.87 MAPT (0.64) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL1136833 0.87 MAPT (0.64) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL689414 0.87 GPR119 (0.56) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL20306312 0.86 MAPT (0.62) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL23355487 0.85 MAPT (0.61) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL31544598 0.85 MAPT (0.61) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL8858016 0.85 MAPT (0.61) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL3709870 0.85 MAPT (0.61) MAPTLMNAALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119118959-A Preparation method of 4- [4- (aminomethyl) phenyl ] piperazine-1-carboxylic acid tert-butyl ester 镇江市高等专科学校 2024-12-13 CN claimed
US-12421229-B2 Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2025-09-23 US disclosed
WO-2025147756-A1 VIRAL SENSITIZERS COMPOSITIONS, METHODS AND USES THEREOF OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2025-07-17 WO disclosed
CN-119118959-A Preparation method of 4- [4- (aminomethyl) phenyl ] piperazine-1-carboxylic acid tert-butyl ester 镇江市高等专科学校 2024-12-13 CN disclosed
CN-119118959-A Preparation method of 4- [4- (aminomethyl) phenyl ] piperazine-1-carboxylic acid tert-butyl ester 镇江市高等专科学校 2024-12-13 CN disclosed
CN-119118959-A Preparation method of 4- [4- (aminomethyl) phenyl ] piperazine-1-carboxylic acid tert-butyl ester 镇江市高等专科学校 2024-12-13 CN disclosed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
CN-114761406-B Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2024-04-19 CN disclosed
EP-4069693-B1 HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES HOFFMANN LA ROCHE (CH) 2024-03-20 EP disclosed
EP-3623369-B1 NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN LA ROCHE (CH) 2023-10-25 EP disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
CN-101910168-A Tropane compounds EXELIXIS INC 2010-12-08 CN disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
US-20100144714-A1 DERIVATIVES OF IMIDAZO PYRIMIDO AND DIAZEPINE PYRIMIDINE-DIONE, AND USE THEREOF AS A DRUG SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2010-06-10 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
US-20090318456-A1 SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-12-24 US disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421229-B2 Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease TLR7, TLR9, TLR1 MAPT 4664/4885LMNA 2972/4885ALDH1A1 1963/4885
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 MAPT 4544/4885LMNA 2251/4885ALDH1A1 2743/4885
US-20090318456-A1 SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS HAVCR2, TYMP, HCCS MAPT 4265/4885LMNA 2499/4885ALDH1A1 3028/4885
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 MAPT 4259/4885LMNA 1130/4885ALDH1A1 2902/4885
US-20100144714-A1 DERIVATIVES OF IMIDAZO PYRIMIDO AND DIAZEPINE PYRIMIDINE-DIONE, AND USE THEREOF AS A DRUG CNR1, CNR2, TBXA2R MAPT 3668/4885LMNA 3153/4885ALDH1A1 1911/4885
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 MAPT 586/4885LMNA 486/4885ALDH1A1 323/4885
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP MAPT 4/4885LMNA 1913/4885ALDH1A1 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.